A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
PHASE1CompletedINTERVENTIONAL
Enrollment
32
Participants
Timeline
Start Date
November 30, 1995
Primary Completion Date
June 30, 1996
Study Completion Date
June 30, 1996
Conditions
Psoriasis Vulgaris
Interventions
DRUG
Abatacept
Trial Locations (1)
Unknown
California Clinical Trials Medical Group, Beverly Hills
NCT00277225 - A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris | Biotech Hunter | Biotech Hunter